Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biogen says it is leader of MS research

Biogen says it is leader of MS research

16th April 2009

Biogen is at the forefront of research and development for treatments of multiple sclerosis (MS), it has asserted.

Two therapies ? Tysabri and Avonex – have been approved and additional compounds are currently under development.

One included in the company’s pipeline – PEGylated interferon beta-1a ? is expected to enter phase III clinical trials within a few months time, explained Michael Panzara, vice-present and chief medical officer of neurology at Biogen.

He added the company has been “a pioneer” in the field for over ten years – with compounds now promising to be “a significant evolution” in the area.

“Biogen ? is redefining success for patients living with MS,” Mr Panzara remarked.

“We are even seeing some clinical trial patients who are free from MS disease activity or with physical improvement from what was seen at baseline.”

Representatives from the business are due to discuss its work at the 61st Annual Meeting of the American Academy of Neurology from April 25th to May 2nd.

Last month, Biogen announced that Robert A Hamm has been appointed chief operating officer of the firm.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.